Home › Compare › HSTO vs QYLD

HSTO vs QYLD: Dividend Comparison 2026

HSTO yields 10000.00% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HSTO wins by $55137509079256512.00M in total portfolio value
10 years
HSTO
HSTO
● Live price
10000.00%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$55137509079256512.00M
Annual income
$54,073,795,673,722,890,000,000.00
Full HSTO calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — HSTO vs QYLD

📍 HSTO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHSTOQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HSTO + QYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
HSTO pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HSTO
Annual income on $10K today (after 15% tax)
$850,000.00/yr
After 10yr DRIP, annual income (after tax)
$45,962,726,322,664,450,000,000.00/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, HSTO beats the other by $45,962,726,322,664,450,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HSTO + QYLD for your $10,000?

HSTO: 50%QYLD: 50%
100% QYLD50/50100% HSTO
Portfolio after 10yr
$27568754539628256.00M
Annual income
$27,036,897,836,861,443,000,000.00/yr
Blended yield
98.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on HSTO right now

HSTO
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-29.6
Piotroski
1/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HSTO buys
0
QYLD buys
0
No recent congressional trades found for HSTO or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHSTOQYLD
Forward yield10000.00% ✓11.92%
Annual dividend / share$2.00$2.04 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$55137509079256512.00M ✓$25.4K
Annual income after 10y$54,073,795,673,722,890,000,000.00 ✓$5,659.31
Total dividends collected$55066727460582336.00M ✓$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: HSTO vs QYLD ($10,000, DRIP)

YearHSTO PortfolioHSTO Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$1,010,700$1,000,000.00$10,352$1,192.36+$1.00M → HSTO
2$95,539,393$94,457,943.93$10,830$1,347.57+$95.53M → HSTO
3$8,447,007,736$8,344,780,585.66$11,460$1,539.07+$8447.00M → HSTO
4$698,565,746,383$689,527,448,105.17$12,275$1,777.84+$698565.73M → HSTO
5$54,040,711,670,213$53,293,246,321,583.74$13,323$2,078.95+$54040711.66M → HSTO
6$3,910,851,616,519,516$3,853,028,055,032,387.00$14,667$2,463.34+$3910851616.50M → HSTO
7$264,781,167,546,477,440$260,596,556,316,801,570.00$16,396$2,960.57+$264781167546.46M → HSTO
8$16,772,556,223,821,672,000$16,489,240,374,546,942,000.00$18,631$3,612.97+$16772556223821.65M → HSTO
9$994,124,678,068,810,000,000$976,178,042,909,320,800,000.00$21,548$4,482.15+$994124678068810.00M → HSTO
10$55,137,509,079,256,515,000,000$54,073,795,673,722,890,000,000.00$25,398$5,659.31+$55137509079256512.00M → HSTO

HSTO vs QYLD: Complete Analysis 2026

HSTO — Stock

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.

Full HSTO Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this HSTO vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HSTO vs SCHDHSTO vs JEPIHSTO vs OHSTO vs KOHSTO vs MAINHSTO vs XYLDHSTO vs JEPQHSTO vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.